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AbstrAct
ATR is an attractive target in cancer therapy because it signals replication stress 
and DNA lesions for repair and to S/G2 checkpoints. Cancer-specific defects in the 
DNA damage response (DDR) may render cancer cells vulnerable to ATR inhibition 
alone. We determined the cytotoxicity of the ATR inhibitor VE-821 in isogenically 
matched cells with DDR imbalance. Cell cycle arrest, DNA damage accumulation and 
repair were determined following VE-821 exposure.
Defects in homologous recombination repair (HRR: ATM, BRCA2 and XRCC3) 
and base excision repair (BER: XRCC1) conferred sensitivity to VE-821. Surprisingly, 
the loss of different components of the trimeric non-homologous end-joining (NHEJ) 
protein DNA-PK had opposing effects. Loss of the DNA-binding component, Ku80, 
caused hypersensitivity to VE-821, but loss of its partner catalytic subunit, DNA-PKcs, 
did not. Unexpectedly, VE-821 was particularly cytotoxic to human and hamster cells 
expressing high levels of DNA-PKcs. High DNA-PKcs was associated with replicative 
stress and activation of the DDR. VE-821 suppressed HRR, determined by RAD51 focus 
formation, to a greater extent in cells with high DNA-PKcs.
Defects in HRR and BER and high DNA-PKcs expression, that are common in 
cancer, confer sensitivity to ATR inhibitor monotherapy and may be developed as 
predictive biomarkers for personalised medicine.
IntroductIon
The DNA damage response (DDR) is essential to 
maintain genomic stability in the face of the high rate 
of ongoing insult from environmental and endogenous 
sources of DNA damage [1]. The DDR signals DNA 
damage for repair, and to cell cycle checkpoints that 
arrest the cell cycle while repair is being completed. 
The response to DNA double strand breaks (DSBs) and 
collapsed replication forks is particularly crucial as these 
types of damage are difficult to repair. Three PI3-Kinase-
related kinases (PIKKs) ATM (ataxia telangiectasia 
mutated), ATR (ATM and Rad3 related) and DNA-PKcs 
(DNA-dependent protein kinase catalytic subunit) recruit 
DNA repair proteins and activate cell cycle checkpoints 
in response to these lesions [2]. ATR is arguably the most 
versatile of these three PIKKs because it is activated 
by regions of single-stranded DNA that occur during 
nucleotide excision repair, following resection of DNA 
DSBs and, lesions most critical to replicating cells, 
collapsed replication forks. Activated ATR phosphorylates 
a number of targets involved in homologous recombination 
DNA repair (HRR) and the re-start of replication forks but 
its major target is CHK1 (reviewed in Chen et al. [3]). 
By phosphorylation of CHK1, ATR initiates the S and G2 
checkpoint cascade.
Aberrations in the DDR create the genomic 
instability that is an “enabling characteristic” of cancer [4]. 
Cancer cells commonly have dysregulated G1 cell cycle 
arrest, e.g. due to inactivation of the TP53/RB pathway [5], 
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and rely on their S/G2 checkpoints for survival following 
DNA damage. Exploiting this dependence makes the ATR/
CHK1 axis an attractive target to selectively enhance the 
anti-cancer activity of DNA damaging chemotherapy and 
radiotherapy. CHK1 inhibitors, and more recently ATR 
inhibitors attenuate/abrogate cell cycle arrest and increase 
the cytotoxicity of the major classes of DNA damaging 
anticancer agents preclinically (reviewed in [3]). CHK1 
inhibitors are yet to fulfil their pre-clinical promise 
in clinical trials, possibly because of poor selectivity 
resulting in toxicity in combination (reviewed in [3]). 
Preclinically ATR inhibition has somewhat different 
effects from CHK1 inhibition [6] and if inhibitors could be 
used as single agents toxicities are expected to be minimal 
[7]. Two ATR inhibitors, VX-970 and AZD-6738, are 
currently undergoing clinical evaluation. VX-970 is being 
evaluated both as a single agent and in combination with 
platinum or gemcitabine chemotherapy (clinicaltrials.gov 
identifier: NCT02157792) and AZD-6738 in combination 
with ionising radiation and carboplatin (EudraCT 
identifier: 2013-005100-34 and clinicaltrials.gov identifier: 
NCT02223923 and NCT02264678). 
Exploitation of the dysregulation of the DDR 
by synthetic lethality through the single-agent use of 
inhibitors of other DDR components, exemplified by the 
cytotoxicity of PARP inhibitors in HRR-defective tumours 
[8] is an exciting new paradigm in cancer that led to a 
rapid expansion in PARP inhibitor development. This has 
driven the search for other synthetic lethal interactions 
that could be exploited therapeutically. Recent studies 
with the prototype ATR inhibitor, NU6027, demonstrated 
that it was particularly cytotoxic to cells defective in BER 
(XRCC1 mutant), and synergistic with PARP inhibition 
[9, 10]. ATM and ERCC1-XPF defects are also reported 
to render cells more sensitive to ATR inhibition [11]. We 
therefore sought to identify DDR defects synthetically 
lethal with the ATR inhibitor, VE-821 (the pre-clinical 
lead from which VX-970 was developed), as a single 
agent and to explore the underlying mechanism. 
We confirm that cells lacking ATM or the BER 
scaffold protein, XRCC1, are hypersensitive to ATR 
inhibitor-induced cytotoxicity and identify for the first 
time that defects in HRR components, XRCC3 or BRCA2, 
also confer sensitivity to ATR inhibition. Interestingly, 
while loss of the binding partner of DNA-PKcs, XRCC5 
(Ku80), conferred sensitivity to VE-821, loss of DNA-
PKcs itself conferred resistance and over-expression of 
DNA-PKcs conferred sensitivity. Mechanistic studies 
suggest this is due to increased replicative stress and 
attenuation of HRR function.
results
Ve-821-induced cytotoxicity in dnA repair 
defective chinese hamster cells
In previous studies with VE-821 the greatest 
chemosensitisation was observed in cells lacking ATM [7] 
and VE-821 was synthetically lethal in cells depleted of 
ATM [12]. We show here that V-E5 cells lacking ATM 
are the most sensitive to VE-821 alone with only 1% 
surviving exposure to 30 µM VE-821 compared to 38% 
in the parental V79 Chinese hamster lung cells (p = 0.01) 
(Figure 1A, Table 1). V-C8 cells that are HRR defective, 
by virtue of a BRCA2 mutation, were almost as sensitive 
(8% survival p = 0.04). Restoring BRCA2 function 
through transfection of wt BRCA2 (V-C8 B2) or through 
a reversing mutation (V-C8 PiR) resulted in reduced 
sensitivity to VE-821. 
Chinese hamster ovary AA8 cells were intrinsically 
resistant to single agent VE-821 with 30 µM having 
virtually no impact on viability (Figure 1B). This was not 
due to a failure of ATR inhibition because VE-821 reduced 
pChk1s345 to a similar or greater extent in AA8 cell lines 
compared to V79 cells and M059J cells (Supplementary 
Figure S1). EM9 cells lacking BER function due to 
XRCC1 loss were significantly (p < 0.0001) more 
sensitive to VE-821 with 30 µM killing approximately 
75% (Table 1). The HRR-defective Irs1SF (XRCC3 
mutant) were the most sensitive of the AA8 derivatives 
with only 16% surviving exposure to 30 µM VE-821. The 
UV5 cells that are nucleotide excision repair defective due 
to ERCC2 mutation were also significantly (p = 0.0002) 
more sensitive than the parental cells, but were the least 
sensitive of all the repair-defective CHO cells. Most 
curious was the data with non-homologous end joining 
(NHEJ) defective cells. Ku70 and Ku80 bind DNA DSB 
and recruit DNA-PKcs to form the catalytically active 
holoenzyme to promote DSB repair. Ku80-defective xrs6 
cells showed sensitivity comparable with HRR and BER 
defective cells but, surprisingly, the V3 cells, defective in 
DNA-PKcs, were not hypersensitive to VE-821 (Figure 
1B, Table1). Correction of the DNA-PKcs defect by 
transfection of a YAC containing human DNA-PKcs 
rendered the cells (V3-YAC) significantly (p < 0.0001) 
more sensitive to VE-821 (only 40% survival at 30 µM).
Ve-821-induced cytotoxicity in human cells with 
high levels of dnA-PKcs
Because of the unexpected results with the Chinese 
hamster DNA-PKcs proficient and deficient cells we 
investigated the phenomenon further in human malignant 
glioblastoma cells deficient in DNA-PKcs, M059J, and the 
DNA-PKcs overexpressing M059J-Fus-1 cells (hereafter 
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Figure 1: the cytotoxicity of single-agent Ve-821 in cells with different ddr defects. Cells were exposed to varying 
concentrations of VE-821 for 24 hr then allowed to form colonies in drug free medium. Data are mean and standard deviation of 3 independent 
experiments for A. Chinese hamster lung cells: V79 (parental), V-E5 (ATM mutant, checkpoint deficient), V-C8 (BRCA2 mutant, HRR 
defective), V-C8 B2 (V-C8 cells complemented with wt BRCA2) and V-C8 PiR (PARPi-resistant V-C8 with secondary mutation in BRCA2 
restoring function), b. Chinese hamster ovary cells: AA8 (parental wt), EM9 (XRCC1 mutant, BER defective), V3 (DNA-PKcs mutant, 
NHEJ defective), V3-YAC (DNA-PKcs restored with yeast artificial chromosome), Xrs6 (Ku80 mutant, NHEJ defective), UV5 (ERCC2 
mutant, NER defective), Irs1SF (XRCC3 mutant, HRR defective), c. Human glioma cells M059J (DNA-PKcs deficient), M059J-Fus1 
(DNA-PKcs corrected by transfer of part of Chromosome 8) and M059J-Fus1 co-exposed to the DNA-PK inhibitor, NU7441 (1 µM), d. 
Human ovarian cancer cells OSEC2 shDNA-PK (with DNA-PKcs knockdown) and OSEC2 shOT (off target knockdown). Inserts in C and 
D show levels of DNA-PKcs and ATR in the cells.
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called Fus-1 cells for simplicity) (Figure 1C). Fus-1 cells 
were substantially and significantly (p < 0.0001) more 
sensitive to VE-821 with only 16% surviving treatment 
with 10 µM in comparison with the DNA-PK defective 
M059J cells with 67% survival. To determine if DNA-
PKcs kinase activity was responsible we used NU7441, 
a potent and specific DNA-PK inhibitor [13], at a 
concentration of 1 µM (as previously used for chemo- and 
radiosensitisation and approximately 5x the cellular IC
50
 
[14]). Co-exposure of the M059J Fus-1 cells to NU7441 
did not protect from VE-821 cytotoxicity, in fact it 
increased cell kill (10% survival at 10 µM VE-821; Table 
1; Figure 1C). This was not due to an off-target effect 
because NU7441 failed to sensitise M059J cells to VE-
821 (Supplementary Figure S3) Further investigations in 
human ovarian OSEC2 cells (selected because of a high 
intrinsic level of DNA-PKcs with an efficient knockdown: 
A McCormick, unpublished data) revealed that 91% 
DNA-PKcs knockdown resulted in significant protection 
from VE-821 cytotoxicity (Figure 1D, Table 1). Thus, a 
consistent pattern of greater sensitivity of high DNA-PKcs 
expressing cells to VE-821 was seen in 3 independent 
cell line pairs. Differences in sensitivity to VE-821 were 
unlikely to be due to different ATR expression levels 
since ATR levels were equivalent or slightly higher in 
OSEC2 shDNA-PKcs cells (Figure 1D insert), but lower 
in the DNA-PKcs deficient M059J cells (Figure 1C insert) 
when normalised to actin loading control compared to 
their DNA-PKcs expressing counterparts. The greater 
sensitivity of the DNA-PKcs expressing cells was also 
not due to greater inhibition of ATR activity by VE-821 
asVE-821 (10 µM) inhibited CHK1Ser345 phosphorylation 
to a similar extent in both M059J and Fus-1 cells 
(Supplementary Figures S1 and S2). These data suggest 
that the abundance of DNA-PKCS protein, independent 
of its kinase activity, sensitises cells to VE-821-induced 
cytotoxicity.
Interestingly, mining of publically-available data 
suggests that the expression of ATR (ATR) and DNA-PKcs 
(PRKDC) may be tandemly regulated in certain tumours. 
For example, the expression of ATR and PRKDC are 
similarly elevated across diverse glioblastoma subtypes 
compared to normal brain (Figure 2A and 2B) and their 
expression is strongly correlated (Figure 2C).
cMYc protein levels depend on dnA-PKcs
Amplified cMYC may confer replicative stress and 
sensitivity to inhibitors of both ATR and CHK1 [15].  Fus-
table 1: Ve-821 cytotoxicity in cell lines with differing ddr status
species and 
tissue of origin cell line
dnA repair defect/
pathway
Significant difference 
from parental* p=
% survival 
at 10 uM 
Ve-821
% survival at 30 
uM Ve-821
Chinese 
hamster ovary
AA8 Parental wt 97 ± 22† 90.8 ± 18.3
EM9 XRCC1BER p<0.0001 54 ± 6 25.4 ± 10.1
UV5 ERCC2/NER p=0.0002 70 ± 13 51.1 ± 15.2
Irs-1SF XRCC3/HRR p<0.0001 34 ± 20 15.6 ± 13.3
Xrs6 Ku80/NHEJ p<0.0001 53 ± 10 17.8 ± 4.3
V3 DNA-PKcs/NHEJ p=0.9966 96 ± 18 82.6 ± 24.5
V3-YAC Corrected V3 p<0.0001 41 ± 9 40.3 ± 15.2
Chinese 
hamster lung
V79 Parental wt 64 ± 7 38.3 ± 8.7
V-E5 ATM/cell cycle checkpoint p= 0.01 40 ± 13 1.1 ± 0.9
V-C8 BRCA2/HRR p=0.04  41 ± 9 7.7 ± 3.2
V-C8 B2 BRCA2 corrected p=0.17 47 ±14 17.1 ± 7.8
V-C8 PiR BRCA2 revertant p=0.03 47 ± 13 15.1 ± 3.9
Human GBM
M059J DNA-PKcs/NHEJ 67 ± 13
M059-Fus-1 DNA-PKcs corrected p<0.00001 16 ± 4
M059-Fus-1 + 
NU7441
DNA-PKcs corrected 
+ inhibited
p<0.00001 10 ± 2
Human 
ovarian surface 
epithelium
OSEC2 shOT parental 31 ± 20
OSEC2 
shDNA-PKcs DNA-PKcs/NHEJ p = 0.0023 76 ± 17
*Statistical differences between cell sensitivities were calculated using a 2-way ANOVA and the p values shown.
†Data are mean ± standard deviation of the % survival at 10 µM VE-821.
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1 cells contain 7 or 8 copies of chromosome 8 following 
transfection to correct their DNA-PKCS defect (encoded 
by PRKDC located at 8q11.21) [16]  we assessed levels 
of cMYC (also located on chromosome 8 at 8q24.21) in 
both M059J and Fus-1 cells.  Despite containing 3 or 4 
copies of chromosome 8 [17] M059J cells expressed only 
low levels of cMYC whereas Fus-1 cells expressed much 
higher cMYC levels (Figure 3A, Supplementary Figure 
S4). DNA-PKcs may be necessary to stabilise cMYC 
[18] so we determined cMYC levels in OSEC2 cells 
with (shDNA-PK) and without (shOT) silenced DNA-
PKcs (Figure 3A, Supplementary Figure S4) and again 
cMYC levels were lower in cells with reduced DNA-PKcs 
expression.  Therefore the higher levels of cMYC in the 
Fus1 cells and OSEC2 cells could have affected VE821 
sensitivity.
Figure 2: Atr and PrKdc (dnA-PKcs) mrnA expression in glioblastoma subtypes. Data are from publically available 
NCBI Gene Expression Omnibus (GEO) dataset GSE4290 and mean ATR and PRKDC mRNA were normalised to HPRT1. Samples were 
from 23 non-tumour brain (epilepsy patients), 26 astrocytomas, 77 glioblastomas and 50 oligodendrogliomas. A. ATR b. PRKDC c. 
Correlation of ATR and PRKDC mRNA expression using GraphPad Prism version 6.0.
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Figure 3: the interaction between cMyc and dnA-PKcs and the cytotoxicity of Ve-821. A. cMYC expression in M059J, 
M059J-Fus-1, OSEC2 shOT and OSEC2 shDNA-PK cells, upper panel representative Western blot lower panel, data normalised to actin. 
Data are from a single experiment, similar data are shown in Supplementary Figure S4. b. Impact of DNA-PK inhibitor on cMYC stability. 
M059J-Fus-1 cells were exposed (or not) to NU7441 (1 µM) to inhibit DNA-PK and/or cyclohexamide (CHX) to inhibit new protein 
synthesis for the times shown prior to protein extraction and measurement by Western blot, upper panel representative Western blot lower 
panel, data normalised to zero time untreated control. Data are from a single experiment at these time-points. c. DNA-PKcs and cMYC 
levels measured By Western blot (left panel), normalised to Actin loading control (centre panel) and the cytotoxicity of VE-821 in human 
breast epithelial cells, MCF10A and its derivative cMYC-MCF10A (cMYC10A). Data are from a single experiment, with expression data 
confirming data published in [1]
table 2: replication stress in untreated M059J and Fus-1 cells
M059J Fus-1 p
γH2AX 5.12 ± 0.39 (292) 6.49 ± 0.66 (215) 0.059
RAD51 1.36 ± 0.15 (292) 2.27 ± 0.28 (215) 0.002
Data are mean ± standard error of the number of foci per nucleus (with the number of individual nuclei) 
measured in two independent experiments. P values were generated comparing foci in M059J with Fus-1 
cells by unpaired t-test.
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Figure 4: effect of Ve-821 on Ir-induced dnA damage, Hrr, cell cycle arrest and proposed mechanism in dnA-
PKcs deficient and over-expressing cells. A. γH2AX foci in M059J (J) and M059J-Fus-1 (F) treated with VE-821 (1 µM) and before 
or after exposure to 2 Gy IR as shown. b. RAD51 foci in M059J (J) and M059J-Fus-1 (F) treated with VE-821 (1 µM) and before or 
after exposure to 2 Gy IR as shown. c. Cell cycle profiles of M059J and M059J-Fus-1 exposed to VE-821 (1 µM) and 2 Gy IR as shown, 
measured after 24 hr. (Flow cytometry histograms shown in Supplementary Figure S5). d. Potential mechanism: In cells with low/normal 
levels of DNA-PKcs endogenous DNA damage (e.g. ROS-induced SS breaks) that cause stalling of the replication fork signal successfully 
to ATR to promote HRR and cell cycle arrest, ATR inhibition hampers this process but not sufficiently to seriously impact on cell viability. 
However, in cells expressing high levels of DNA-PKcs, this may compete with ATR signalling resulting in reduced HRR, if cells are 
also exposed to a DNA-PK inhibitor this will inhibit autophosphorylation and dissociation so may trap DNA-PKcs on the DNA. The 
postulated attenuation of signalling to HRR via DNA-PKcs obstruction combined with ATR inhibition may be the mechanism underlying 
the significantly compromised cell viability.
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To determine whether DNA-PK activity was 
required to maintain high cMYC levels we investigated 
the effect of NU7441 (1 µM to allow direct comparison 
with the cytotoxicity data) on cMYC levels in Fus-1 cells. 
cMYC is reported to have a short half-life of 20-30 min 
[19]. In our study the levels of cMYC declined less rapidly 
in Fus-1 cells with an estimated half-life of approximately 
2 hours, suggesting some stabilisation. In NU7441-treated 
cells the decline was more rapid and cMYC levels were 
reduced to 50% of the initial level at 30 min (Figure 3B). 
Since NU7441 impaired cMYC stability (Figure 3B) but 
did not protect from VE-821 cytotoxicity, sensitivity to 
VE-821 may not be due to elevated cMYC. To test this 
hypothesis further we used immortalised human breast 
cells, MCF10A and a MYC-amplified derivative (cMYC-
MCF10A) with an approximately 3-fold higher level 
of cMYC expression.  In cytotoxicity assays the MYC-
amplified cells were more resistant rather than more 
sensitive to VE-821 compared to parental cells (Figure 
3C; p < 0.0001). Taken together these data suggest that 
sensitivity to VE-821 is not due to elevated cMYC.
Ve-821 impairs Hrr in irradiated dnA-PKcs 
overexpressing cells
We next investigated if the preferential cytotoxicity 
of VE-821 in cells with high DNA-PKcs levels was due 
to an effect on DNA repair. DNA is continuously being 
damaged at an astonishingly high level (>105 SSBs/
genome/cell/day) largely caused by reactive oxygen 
species that are a by-product of respiration. In replicating 
cells, any remaining un-repaired DNA breaks will cause 
replicative stress, collapsed replication forks and single-
ended DNA DSBs. Such lesions activate ATR, trigger 
phosphorylation of H2AX, visualised by γH2AX foci, and 
are resolved by HRR, visualised by RAD51 foci. Although 
low in the absence of exogenous DNA damage, γH2AX 
foci were modestly (27%, p = 0.059) higher and RAD51 
foci were significantly (67%, p = 0.002) higher in Fus-
1 cells than M059J cells (Table 2), indicative of higher 
levels of replicative stress.
We previously showed that the ATR inhibitor 
NU6027 suppressed RAD51 focus formation, indicating 
that ATR inhibition led to an impairment of HRR [9]. To 
determine if VE-821 also suppressed HRR and to assess 
the impact of DNA-PKcs on HRR we measured γH2AX 
and RAD51 foci in M059J and Fus-1 cells exposed to 2 
Gy ionising radiation (IR) in the presence or absence of 
VE-821 (Figure 4). IR was selected as the DNA damaging 
agent because a) it is effective and commonly used in 
cancer therapy, b) it reliably induces G2 accumulation in 
M059J and Fus-1 cells allowing direct comparison with 
the cell cycle data and c) published data indicates 1 μM 
VE-821 is a potent radiosensitiser [25] Interpretation of 
γH2AX data (Figure 4A) is somewhat complicated by the 
fact that DNA-PKcs is the major kinase responsible for 
H2AX phosphorylation immediately after IR. Previous 
work in our lab indicates that NHEJ is responsible for the 
immediate rapid DSB repair phase after IR and that the 
kinetics of resolution of γH2AX foci closely follows that 
of the resolution of DSB by neutral comet assay [20]. We 
selected 6 and 24 hr as suitable time-points to measure 
γH2AX foci as at these time-points they closely reflect 
DSB measurements. As such, the lower levels of γH2AX 
foci in Fus-1 cells at 6 and 24 hr may reflect the more 
rapid repair, resulting in faster disappearance of γH2AX 
foci. VE-821 caused a reduction in γH2AX foci at 24 
hr, which may reflect an impairment of ATR-mediated 
phosphorylation of H2AX as IR-induced SS breaks 
encounter the replication forks.
Interestingly, VE-821 alone significantly suppressed 
RAD51 focus formation in unirradiated DNA-PKcs 
proficient and deficient cells, but the suppression was more 
profound in Fus-1 cells than in the M059J cells (Figure 
4B, Table 3) suggesting VE-821 impairs HRR-mediated 
repair of endogenous DNA damage/replication stress to 
a greater extent in DNA-PKcs overexpressing cells. There 
were >3x more RAD51 foci in M059J cells than in Fus-1 
cells (p < 0.0001) 24 hr after IR, potentially indicating 
table 3: rAd51 foci pooled data
treatment rAd51 foci/cellM059J Fus-1
Control 1.36 ± 0.15 2.27 ±0.28
10 µM VE-821 0.85 ± 0.11(p=0.007)
1.16 ± 0.16
(p=0.0008)
IR + 6 hr control 8.37 ± 0.69 7.72 ± 0.58
IR + 6 hr 1 µM VE-821 8.01 ± 0.61(p=0.69, NS)
5.18 ± 0.47
(p=0.0007)
IR + 24 hr control 22.94 ± 1.09 6.72 ± 0.69
IR + 24 hr 1 µM VE-821 9.6 ± 0.82(p<0.0001)
2.02 ± 0.84
(p<0.0001)
Data are mean and standard deviation from 2 or more independent experiments where > 100 nuclei were evaluated. 
Significance is given for the effect of VE-821 by comparison with control or contemporaneously irradiated cells in 
the absence of VE-821
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that DNA-PKcs suppresses HRR or that DNA breaks had 
been repaired by the NHEJ pathway. DNA-PKcs may 
also suppress ATR activity as the phosphorylation of 
CHK1 after IR and gemcitabine was lower in Fus-1 than 
M059J cells (Supplementary Figures S1 and S2). VE-821 
significantly (p < 0.0001) reduced RAD51 focus formation 
24 hr post-IR in both cell lines, and, as in the absence 
of exogenous damage, a more profound suppression was 
observed in the Fus-1 cells (3.3-fold) than in the M059J 
cells (2.4-fold). Cumulatively, these data suggest that VE-
821 suppresses HRR to a greater extent in DNA-PKcs 
proficient Fus-1 cells, consistent with DNA-PKCS proficient 
cells being more sensitive to VE-821-induced cytotoxicity.
Ve-821 abrogates G2 arrest in both M059J and 
Fus-1 cells
We next sought to determine if the greater 
cytotoxicity of VE-821 in the DNA-PKcs expressing cells 
was due to a differential effect on cell cycle distribution. 
In parallel experiments to those measuring HRR, IR 
caused G2 accumulation, which was almost completely 
abrogated by 1 μM VE-821 in both cell lines, consistent 
with its inhibition of ATR signalling to the G2 checkpoint 
(Figure 4C) as shown previously in other cell lines [21].
dIscussIon
Clinical studies with molecularly targeted agents 
show that stratification of patients based on the molecular 
pathology of their tumour is critical for success [22]. ATR 
has emerged as an interesting novel target and two ATR 
inhibitors are being tested clinically. The aim of the work 
presented here was to identify molecular determinants 
of sensitivity to ATR inhibitors for patient stratification. 
Since dysregulation of the DNA damage response (DDR) 
is common in cancer, and there is precedent for DDR 
defects to confer sensitivity to DDR inhibitors (HRR 
defects and PARP inhibitors)), we focussed on DDR 
defects as potential determinants of sensitivity to single 
agent ATR inhibition.
BER and HRR are complementary pathways in the 
repair of endogenous DNA damage. It is clear that VE-821 
impairs HRR since it causes a profound suppression of 
RAD51 focus formation after IR (Figure 4B). By analogy 
with the synthetic lethality of PARPi (which suppresses 
BER) in HRR-defective cells, the reciprocal synthetic 
lethality is also predicted, where inhibition of HRR by 
VE-821 is synthetically lethal with defects in BER as 
indicated by the hypersensitivity of the BER-defective 
EM9 cells confirming our previous results with another 
ATR inhibitor, NU6027 [9]. BER defects have been 
reported widely in a variety of cancer types (reviewed 
in [23]) and selection of patients based on tumour BER 
status for ATR inhibitor monotherapy may be a useful 
therapeutic manoeuvre.
The hypersensitivity of ATM-defective cells was 
also not unexpected because VE-821 had previously been 
shown to be cytotoxic to cells in which ATM had been 
knocked down [11]. Moreover, recent data, reported in 
abstract form only, indicate that the ATR inhibitor AZD-
6738 was synthetically lethal in ATM-defective CLL cells 
from patients [12]. ATM is thought to contribute to HRR 
[24] and we found that other HRR defects also conferred 
sensitivity: Irs1SF cells defective in XRCC3 (a RAD51 
related protein) were the most sensitive to VE-821 and 
BRCA2-mutant cells showed a similar level of sensitivity 
to the ATM mutants. Thus, although ATR inhibitors are 
thought to principally modulate HRR, synthetic lethality 
can be achieved in cells that already have defects in 
components of HRR, indicating that epistasis is not an 
issue. This is consistent with the observation that defects 
in the ATR signalling pathway conferred substantial 
synthetic lethality with ATR and CHK1 inhibitors and 
analogous to recent data showing that XRCC1-/- cells 
are hypersensitive to PARP inhibitors [25]. These data 
suggest that ATR inhibitors may have activity in several 
tumour types because HRR defects are common in cancer, 
not just those associated with BRCA1/2 mutations [26]. 
The potential could be very broad indeed as hypoxia, a 
common occurrence in tumours that promotes a more 
aggressive phenotype, actually causes a downregulation of 
HRR proteins that is exploitable by “contextual synthetic 
lethality” [2]. Indeed, this may underlie the cytotoxicity 
and radiosensitisation by VE-821 in hypoxic cells [27]. 
In contrast to reports that ERCC1, a nuclease in the 
NER pathway was synthetically lethal with ATR inhibition 
[11], dysfunction of ERCC2 (XPD), a helicase upstream 
of ERCC1 in the NER pathway, only conferred a modest 
sensitivity to VE-821. ERCC1 also participates in multiple 
DNA repair pathways, including cross-link repair and 
HRR [28] that may contribute to the sensitivity to VE-
821.Therefore, not all DDR defects confer substantial 
sensitivity to ATR inhibitors.
Our most surprising observation was that cells 
defective in DNA-PKcs were not sensitive to VE-821 
but VE-821 was profoundly cytotoxic to cells that over-
expressed DNA-PKcs. The initial observation in CHO 
cells was confirmed in two isogenic pairs of human cancer 
cell lines. The kinase function of DNA-PKcs was not 
responsible because co-exposure to the DNA-PK inhibitor, 
NU7441 increased, rather than decreased, sensitivity 
to VE-821. Similarly, the Ku80-defective cells were 
sensitive rather than resistant to VE-821 suggesting that 
NHEJ function was not responsible. However, it should be 
noted that Ku80 has other functions besides NHEJ, such as 
telomere maintenance [29, 30] a possible role in BER [31] 
and it has been implicated in HRR through its interaction 
with BRCA1 [32]. Since both BER and HRR defects 
confer sensitivity to VE-821 the sensitivity of Ku80 
defective cells may reflect these alternative functions.
Oncotarget32405www.impactjournals.com/oncotarget
Overexpression of cMYC has previously been 
shown to cause replicative stress and confer sensitivity 
to CHK1 inhibitors and ATR knockdown [15, 33]. 
Since correction of the DNA-PKcs defect in Fus-1 cells 
involves amplifying chromosome 8 and that the cMYC 
gene is also on chromosome 8 we investigated if cMYC 
was implicated in the VE-821-sensitivity of DNA-PKcs 
over-expressing cells. Fus-1 cells did have significantly 
higher levels of cMYC and γH2AX and RAD51 foci, 
suggesting a higher level of replication stress (Figure 
4A/B). However, when tested in another cell background, 
without manipulation of DNA-PKCS, cMYC over-
expressing cells were resistant rather than sensitive to 
VE-821 indicating that it is the elevated DNA-PKcs 
rather than cMYC that dictates VE-821 sensitivity. We 
hypothesise that DNA-PKcs over-expression, which is 
common in cancer [34], causes genomic instability by 
competition with HRR and needs to be balanced by an 
increase in ATR to allow the growth of the tumour. Indeed, 
data mining confirms that, in gliomas at least, there is a 
strong correlation between ATR and PRKDC transcripts. 
The higher level of RAD51 foci in Fus-1 cells compared 
to M059J cells was accompanied by a higher G2 fraction 
that may also indicate increased replication stress and 
dependence on G2 checkpoint signalling. VE-821 caused 
a much greater reduction in RAD51 and slightly greater 
reduction in the G2 fraction in untreated Fus-1 cells. This 
suggests that in DNA-PKcs overexpressing cells VE-821 
has a greater impact on HRR and checkpoint activation in 
response to endogenous damage. Following exposure to 
IR there was a greater increase in RAD51 foci in M059J 
cells compared to Fus-1 cells, suggesting that HRR was 
more active in DNA-PKcs defective cells. Remarkably, 
VE-821 caused a greater suppression of RAD51 foci in 
the Fus-1 cells, confirming its greater impact on HRR in 
the DNA-PKcs expressing cells. Several studies suggest 
that NHEJ competes with HRR in the response to DNA 
DSBs (reviewed in [35]) and indeed the deletion of 53BP1 
or DNA-PKcs can restore HRR function in BRCA mutant 
cells [36]. Our data are largely in agreement with these 
observations but suggest that different components of 
NHEJ are more important for this competition than others. 
Thus, Ku80 and the NHEJ pathway per se may not be 
critical, but DNA-PKcs may hamper HRR. Since HRR is 
a high fidelity pathway and specifically associated with 
stalled replication forks (likely to be the most abundant 
endogenous DS lesions) it is the pathway principally used 
to maintain viability in the absence of exogenous DNA 
damage. Indeed, whereas HRR is critical for genomic 
stability, NHEJ, which is more error-prone, has been 
implicated in promoting genomic instability and cancer 
development [35]. 
In contrast to reports that DNA-PK inhibition (with 
NU7441) also restored HRR function and resistance 
to PARPi in BRCA mutant cells [36], we found that 
NU7441 actually increased sensitivity to VE-821. DNA-
PKcs autophosphorylation is thought to be necessary 
for its dissociation from DNA for the NHEJ pathway 
to complete DSB repair. Based on our observations we 
speculate that increased DNA-PKcs levels increases the 
chance of binding to DNA DSB potentially obstructing the 
recruitment of some components of the HRR machinery 
(Figure 4D). We further speculate that this potential 
impairment of HRR causes hypersensitivity to VE-821, 
similar to that experienced by HRR defective cells. The 
observation that NU7441 further sensitised Fus-1 cells to 
VE-821 may suggest that inhibition of the kinase activity 
could hinder DNA-PKcs dissociation and hence further 
impair recruitment of the HRR machinery. This would 
be analogous to PARP inhibitors which, by preventing 
PARP-1 auto-ADP-ribosylation and dissociation from 
DNA breaks, have a more profound effect on their repair 
than does depletion of the enzyme [37]. Similarly, ATM 
inhibition is more detrimental than ATM knockdown, 
through inhibiting ATM dissociation from the DNA 
thereby causing a physical impediment [8, 38]. Further 
investigations would be necessary to determine the 
therapeutic potential of DNA-PKcs and ATR inhibitor 
combinations. 
HRR defects due to BRCA mutations are already 
known to confer sensitivity to both conventional cytotoxic 
agents (especially cisplatin) and molecularly targeted 
agents (PARPi). Our observations that BER defects and 
high levels of DNA-PKcs confer sensitivity to ATR 
inhibition are therefore novel and exciting. Whilst the 
sensitivity of cells with these imbalances in the DDR to 
ATR inhibition may not be quite as striking as reported 
originally for BRCA mutations and PARP, they are 
similar to our previous determination of sensitivities of 
HRR-defective human cancer cells to PARP inhibition 
[39] and other synthetic lethalities with ATM and ATR 
inhibition [40] and reviewed in [41]). As stated above, 
both BER defects and high NHEJ can be sufficient to 
promote genomic instability leading to cancer formation. 
Several cancers have defects in BER and/or overexpress 
DNA-PKcs [23, 34]. Over-expression of DNA-PKcs 
may be linked to disease progression, and our own data 
indicate that this is the case in liver cancer [42]. The data 
presented here indicate that BER defects and DNA-PKcs 
overexpression are exploitable with the ATR inhibitor, 
VE-821 and may prove to be predictive biomarkers for 
personalised medicine with the ATR inhibitors that are in 
clinical trials (https://www.clinicaltrials.gov/ct2/results?te
rm=ATR+inhibitor&pg=1).
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MAterIAls And MetHods
chemicals and reagents
Routine chemicals and reagents were obtained 
from Sigma Aldrich (Poole, UK) unless otherwise stated. 
The ATR inhibitor VE-821 (Vertex Pharmaceuticals 
(Europe) Ltd Abingdon, UK)VE-821 and the DNA-PK 
inhibitor NU7441 (kind gift from Celine Cano, Newcastle 
University, UK) were dissolved in DMSO and stored at 
-20°C. 
cell lines
Parental Chinese hamster ovary (CHO) cells (AA8) 
and their repair-defective derivatives: Irs1SF (XRCC3 
defective: BER), xrs6 (Ku80 defective: NHEJ), V3 
(DNA-PKCS defective: NHEJ) and V3-YAC cells (V3 cells 
complemented with human DNA-PKCS) were a kind gift 
from Professor Penny Jeggo (Sussex University, Brighton, 
UK). EM9 (XRCC1 defective), and UV5 (ERCC2 
defective) were obtained from American Type Culture 
Collection (ATCC, VA, USA). All CHO cells were grown 
in RPMI 1640 media supplemented with 10% FBS. V3-
YAC cells were grown in medium with G418 (400 µg/ml). 
Parental Chinese hamster lung fibroblast (CHL) cells 
(V79) and their repair-defective derivatives V-E5 (ATM 
defective) were a kind gift from Professor Srinivasan 
Madhusudan (Nottingham University, UK). VC8 (BRCA2 
defective;HRR) V-C8-B2 (VC8 cells complemented with 
human BRCA2 and V-C8 PiR (VC8 clone spontaneously 
resistant to PARP inhibitors, [43]) , kindly provided by 
Professor Thomas Helleday (Karolinska, Stockholm) were 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% FBS. V-C8 B2 cells were grown 
in medium with G418 (400 µg/ml).
MCF-10A cells were purchased from American 
Type Culture Collection (ATCC, VA, USA) and 
authenticated by SNP 6.0 and published karyotype data, 
[44, 45]. Myc-MCF-10A cells were generated by exposing 
cells to 5 Gy fractionated doses of ionising-radiation to a 
cumulative dose of 80 Gy as previously described in [1]. 
MCF-10A and Myc-MCF-10A cells were maintained in 
Dulbecco’s Modified Eagle’s Medium: Nutrient Mixture 
F-12 (DMEM-F12) containing 5% (v/v) horse serum, 20 
ng/ml epidermal growth factor, 0.5 μg/ml hydrocortisone, 
100 ng/ml cholera toxin and 10 μg/ml insulin. 
M059J, DNA-PKcs-deficient human glioblastoma 
cells [17], were grown in DMEM supplemented with 10% 
FBS. M059J-Fus-1 (M059J transfected with a portion of 
chromosome 8 carrying the DNA-PKcs gene; [16]) cells 
were cultured in full media with 400 µg/ml G418. Cells 
were authenticated by STR profiling (LGC Standards, 
Teddington UK). Knockdown models were generated by 
transfection of OSEC2 cells [46] with viral particles made 
using Mission lentiviral packaging mix (Sigma-Aldrich) 
as per manufacturer’s protocol. OSEC shOT (containing 
MISSION® pLKO.1-puro Non-Target shRNA Control 
Plasmid DNA) or OSEC shDNA PK (containing PRKDC 
MISSION shRNA Lentiviral Transduction Particles;
sequence:CCGGGCAGATAGAAAGCATTA
CATTCTCGAGAATGTAATGCTTTCTATCTGCTT
TTT; TRCN0000006255) were generated. Following 
transfection, cells stably expressing the appropriate 
shRNA constructs were selected for by culturing in 
HEPES modified RPMI-1640 containing 10% FBS, 100 
unit/ml penicillin/streptomycin and 400 µg/mL G418) and 
incubated at 33oC with 5% CO2. 
cytotoxicity assays
Exponentially growing cells were counted and 
seeded at known low densities into 6-well tissue culture 
plates and allowed to adhere overnight. Cells were treated 
with a range of VE-821 concentrations in 0.1% DMSO 
in complete medium for 24 hours and control cells were 
exposed to 0.1% DMSO. Surviving cells were allowed 
to grow in fresh drug-free media for 1-2 weeks to form 
colonies (> 30 cells) prior to fixation (75% methanol, 
25% glacial acetic acid), staining (1% crystal violet) and 
counting. Survival was calculated by reference to the 
DMSO controls. 
Western blotting
Samples of exponentially growing cells were 
harvested by brief trypsinisation and protein extracted by 
re-suspending the cell pellet in Phosphosafe Extraction 
Reagent (Merck, EMD Millipore, MA, USA) containing 
protease inhibitor cocktail at room temperature for 10 
minutes followed by brief sonication. 30 µg of protein 
for each sample was analysed by SDS PAGE and Western 
blotting unless otherwise stated. Actin was detected 
using a 1:10,000 dilution of THE™ beta Actin Antibody 
(Genscript, NJ, USA), cMYC using a 1:5000 dilution of 
Anti-cMYC [Y69] antibody (Abcam, Cambridge, UK), 
ATR using a 1:300 dilution of ATR Antibody N-19 (Santa 
Cruz Biotechnology Inc, TX, USA) and DNA-PK using 
a 1:300 dilution of DNA-PKcs Antibody (H-163) (Santa 
Cruz Biotechnology Inc, TX, USA) all were incubated 
overnight at 4oC. HRP-conjugated secondary antibodies; 
Goat anti-rabbit IgG-HRP, Goat anti-mouse IgG-HRP 
(Dako, Cambridge, UK) and Donkey anti-goat IgG-HRP 
(Santa Cruz Biotechnology Inc, TX, USA) were all used 
at a 1:1000 dilution and incubated for 1 hour at room 
temperature. Image capture and analysis were carried out 
using the Fuji LAS-300 Image Analyser System (Raytek, 
Sheffield UK).
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cMYc stability
Exponentially growing M059J and M059J-Fus-1 
cells were treated with 1 µM NU7441 and 40 µg/mL 
cyclohexamide and incubated for 0, 30, 60, 120 or 240 
minutes as indicated prior to protein extraction and 
western blotting as described above.
dnA damage and repair assays
Cells seeded onto coverslips at a density of 0.5 x 
105 cells/ml were allowed to adhere for 24 hr then treated 
with VE-821 and/or NU7441 at the concentrations stated 
for 1 hour prior to 2 Gy X-ray irradiation. Cells were then 
incubated for 6 and 24 hours prior to fixing with ice cold 
methanol at -20oC. Immunofluorescence microscopy for 
phospho-Histone H2AX (Ser 139; γH2AX) and RAD51 
foci was carried out as described previously [47]. The 
number of γH2AX and RAD51 foci was determined in > 
50 cells per condition using ImageJ software and a custom 
macro [48]. 
Cell cycle analysis by flow cytometry
Approximately 1 million cells were seeded into 
tissue culture dishes and allowed to adhere overnight. 
Cells were treated with VE-821 and/or NU7441 at 
the concentrations stated and/or 2 Gy X-irradiation. 
Where irradiation was used cells were pre-treated with 
VE-821/NU7441 for 1 hour. After 24 hours, cells were 
trypsinised and fixed in ice cold methanol stored overnight 
at -20°Cthen washed in PBS and stained using PBS 
containing 200 µg/ml propidium iodide and 200 µg/ml 
RNAase A. Following incubation for at least 30 minutes 
in subdued light, cells were analysed using a FACSCalibur 
Flow cytometer (BD Biosciences, San Jose, CA, USA) 
using a 488 laser. At least 20,000 events were counted 
and analysed using Cyflogic analysis software (Cyflo Ltd, 
Turku, Finland).
Mining of publically available mrnA expression 
data
mRNA expression profiles were obtained from the 
publically available NCBI Gene Expression Omnibus 
(GEO). mRNA expression data from the GEO dataset 
GSE4290 was used and mean ATR and PRKDC (gene 
encoding DNA-PKCS) mRNA levels, measured by 
multiple probes on the Affymetrix Human Genome 
U133 Plus 2.0 Array, were normalised to that of the 
most consistently expressed housekeeping gene; HPRT1. 
Samples where information from appropriate probes 
was available included 23 normal (epilepsy patients) 
samples, 26 astrocytomas, 77 glioblastomas and 50 
oligodendrogliomas. mRNA expression was compared and 
correlated using GraphPad Prism version 6.0.
statistical analysis
Statistical analysis was performed using GraphPad 
Prism 6.0 (San Diego, CA, USA). Paired or unpaired 
t-tests were performed as indicated and, where clonogenic 
survival was assessed, groups were compared using 
a 2-way ANOVA with application of a Bonferroni 
correction. Differences were deemed significant when p 
< 0.05.
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